Home / Market News / $ERAS
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015

Nov 18, 2026, 12:36 PM UTC · Primary ticker $ERAS

Erasca and Bristol Myers Squibb are collaborating on a Phase 1/2 clinical trial for MTAP-deleted pancreatic cancer, combining Erasca's ERAS-0015 with BMS's navlimetostat. This partnership provides Erasca with a significant clinical development opportunity and validates its asset, while BMS expands its oncology pipeline.

Erasca has entered a clinical collaboration with Bristol Myers Squibb to evaluate ERAS-0015 in combination with navlimetostat for MTAP-deleted pancreatic cancer. This is a positive development for Erasca as it validates their pan-RAS molecular glue and provides a funded pathway for clinical development with a major pharmaceutical partner, reducing their financial burden and risk. For Bristol Myers Squibb, it represents an expansion of their oncology pipeline and a potential new therapeutic avenue. In the short term, this could lead to increased investor confidence in Erasca. Long-term implications depend on the trial's success, which could significantly boost Erasca's valuation and offer a new treatment option for a difficult-to-treat cancer. The key opportunity for traders is in ERAS, given the potential for significant upside if early trial results are positive.

$ERAS positive Clinical collaboration for key asset
$BMY neutral Expands oncology pipeline, but minor impact on large cap
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.